Increased levels of macrophage-secreted cathepsin S during prostate cancer progression in TRAMP mice and patients

Cancer Genomics and Proteomics

Volumn 6, Issue 3, 2009, Pages 149-160

  Lindahl, Charlotta ^a   Simonsson, Monika ^a   Bergh, Anders ^a   Thysell, Elin ^a   Antti, Henrik ^a   Sund, Malin ^a   Wikström, Pernilla ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Immunohistochemistry; Proteomics; Tumour marker; Western blot

Indexed keywords

CATHEPSIN S; CD68 ANTIGEN; COLLAGEN TYPE 4; KALININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CASTRATION; CELL INFILTRATION; EXPERIMENTAL MODEL; FEMALE; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MACROPHAGE; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SAMPLE; TUMOR DIFFERENTIATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

MUS;

EID: 67649506542     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Riethdorf S and Pantel K: Disseminated tumour cells in bone marrow and circulating tumour cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology 75: 140-148, 2008. (Pubitemid 351820732)
2. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J and Zincke H: Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 164: 101-105, 2000. (Pubitemid 30434268)
3. Han M, Partin AW, Pound CR, Epstein JI and Walsh PC: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28: 555-565, 2001.
4. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspjnall JO, Cunha GR, Donjacour AA, Matusik RJ and Rosen JM: Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92: 3439-3443, 1995.
5. Wikström P, Lindahl C and Bergh A: Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy. Prostate 62: 148-164, 2005. (Pubitemid 40096781)
6. Turk V, Turk B and Turk D: Lysosomal cysteine proteases: facts and opportunities. EMBO J 20: 4629-4633, 2001. (Pubitemid 32848615)
7. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V and Turk B: Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm 13: 387-403, 2007. (Pubitemid 46477760)
8. Buck MR, Karustis DG, Day NA, Honn KV and Sloane BF: Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 282: 273-278, 1992.
9. Mohanam S, Jasti SL, Kondraganti SR, Chandrasekar N, Lakka SS, Kin Y, Fuller GN, Yung AW, Kyritsis AP, Dinh DH, Olivero WC, Gujrati M, Ali-Osman F and Rao JS: Down-regulation of cathepsin B expression impairs the invasive and tumourigenic potential of human glioblastoma cells. Oncogene 20: 3665-3673, 2001. (Pubitemid 32624958)
10. Mai J, Sameni M, Mikkelsen T and Sloane BF: Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol Chem 383: 1407-1413, 2002. (Pubitemid 35282958)
11. Shi GP, Sukhova GK, Kuzuya M, Ye Q, Du J, Zhang Y, Pan JH, Lu ML, Cheng XW, Iguchi A, Perrey S, Lee AM, Chapman HA and Libby P: Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res 92: 493-500, 2003. (Pubitemid 36368661)
12. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D and Joyce JA: Distinct roles for cysteine cathepsin genes in multistage tumourigenesis. Genes Dev 20: 543-556, 2006. (Pubitemid 43345321)
13. Wang B, Sun J, Kitamoto S, Yang M, Grubb A, Chapman HA, Kalluri R and Shi GP: Cathepsin S controls angiogenesis and tumour growth via matrix-derived angiogenic factors. J Biol Chem 281: 6020-6029, 2006.
14. Fernandez PL, Farre X, Nadal A, Fernandez E, Peiro N, Sloane BF, Shi GP, Chapman HA, Campo E and Cardesa A: Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer 95: 51-55, 2001.
15. Flannery T, Gibson D, Mirakhur M, McQuaid S, Greenan C, Trimble A, Walker B, McCormick D and Johnston PG: The clinical significance of cathepsin S expression in human astrocytomas. Am J Pathol 163: 175-182, 2003. (Pubitemid 36759602)
16. Flannery T, McQuaid S, McGoohan C, McConnell RS, McGregor G, Mirakhur M, Hamilton P, Diamond J, Cran G, Walker B, Scott C, Martin L, Ellison D, Patel C, Nicholson C, Mendelow D, McCormick D and Johnston PG: Cathepsin S expression: An independent prognostic factor in glioblastoma tumours - a pilot study. Int J Cancer 119: 854-860, 2006. (Pubitemid 44051449)
17. Kos J, Sekirnik A, Kopitar G, Cimerman N, Kayser K, Stremmer A, Fiehn W and Werle B: Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis. Br J Cancer 85: 1193-1200, 2001. (Pubitemid 33052320)
18. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML and Rosen JM: The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 8: 230-239, 1994. (Pubitemid 24067110)
19. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA and Greenberg NM: Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55: 219-237, 2003. (Pubitemid 36532401)
20. Lissbrant IF, Stattin P, Wikström P, Damber JE, Egevad L and Bergh A: Tumour associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 77: 445-451, 2000.
21. Wikström P, Ohlson N, Stattin P and Bergh A: Nuclear androgen receptors recur in the epithelial and stromal compartments of malignant and non-malignant human prostate tissue several months after castration therapy. Prostate 67: 1277-1284, 2007. (Pubitemid 47435775)
22. Bylesjö M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E and Trygg J: OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemometr 20: 341-351, 2006.
23. Altenberg B and Greulich KO: Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84: 1014-1020, 2004. (Pubitemid 39469126)
24. Liuzzo JP, Petanceska SS, Moscatelli D and Devi LA: Inflammatory mediators regulate cathepsin S in macrophages and microglia: A role in attenuating heparan sulfate interactions. Mol Med 5: 320-333, 1999. (Pubitemid 29342967)
25. Ruddat VC, Whitman S, Klein RD, Fischer SM and Holman TR: Evidence for downregulation of calcium signaling proteins in advanced mouse adenocarcinoma. Prostate 64: 128-138, 2005. (Pubitemid 40791762)
26. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M and Hanahan D: Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumourigenesis. Cancer Cell J: 443-453, 2004. (Pubitemid 38610246)
27. Halin S, Häggström Rudolfsson S, Van Rooijen N and Bergh A: Extratumoural macrophages promote tumour and vascular growth in an orthotopic rat prostate tumour model. Neoplasia 11: 177-186, 2009.
28. Rudolfsson S and Bergh A: Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target. Expert Opin Ther Targets 13: 219-225, 2009.
29. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251: 1451-1455, 1991. (Pubitemid 121000430)
30. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W and van Roy F: Genetic manipulation of E-cadherin expression by epithelial tumour cells reveals an invasion suppressor role. Cell 66: 107-119, 1991. (Pubitemid 121001351)
31. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM and Schalken JA: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54: 3929-3933, 1994. (Pubitemid 24241218)
32. Miyake H, Hara I and Eto H: Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression. Anticancer Res 24: 2573-2577, 2004. (Pubitemid 39166350)
33. Nagler DK, Kruger S, Kellner A, Ziomek E, Menard R, Buhtz P, Krams M, Roessner A and Kellner U: Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia. Prostate 60: 109-119, 2004. (Pubitemid 38758576)
34. Hara I, Miyake H, Yamanaka K, Hara S and Kamidono S: Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression. Oncol Rep 9: 1379-1383, 2002.
35. Waghray A, Keppler D, Sloane BF, Schuger L and Chen YQ: Analysis of a truncated form of cathepsin H in human prostate tumour cells. J Biol Chem 277: 11533-11538, 2002. (Pubitemid 34952924)
36. Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL and Gleason DF: Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma. Cancer 94: 3141-3149, 2002. (Pubitemid 34670497)
37. Jiborn T, Abrahamson M, Gadaleanu V, Lundwall A and Bjartell A: Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation. BJU Int 98: 189-196, 2006. (Pubitemid 43885530)
38. Le Gall C, Bellahcene A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J and Clezardin P: A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumour burden. Cancer Res 67: 9894-9902, 2007. (Pubitemid 47621238)
39. Palermo C and Joyce JA: Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 29: 22-28, 2008.
40. Grimm J, Kirsch DG, Windsor SD, Kim CF, Santiago PM, Ntziachristos V, Jacks T and Weissleder R: Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc Natl Acad Sci USA 102: 14404-14409, 2005.
41. Blum G, von Degenfeld G, Merchant MJ, Blau HM and Bogyo M: Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat Chem Biol 3: 668-677, 2007. (Pubitemid 47417706)
42. Bell-McGuinn KM, Garfall AL, Bogyo M, Hanahan D and Joyce JA: Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumour growth and invasiveness in a mouse model of multistage cancer. Cancer Res 67: 7378-7385, 2007. (Pubitemid 47206568)